NCT02129075 - A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 9, 2014

Primary Completion Date

March 28, 2016

Study Completion Date

May 18, 2018

Conditions

Cutaneous MelanomaMelanomaMelanoma of Unknown PrimaryMucosal MelanomaOcular MelanomaStage IIB Cutaneous Melanoma AJCC v6 and v7Stage IIC Cutaneous Melanoma AJCC v6 and v7Stage III Cutaneous Melanoma AJCC v7Stage IIIA Cutaneous Melanoma AJCC v7Stage IIIB Cutaneous Melanoma AJCC v7Stage IIIC Cutaneous Melanoma AJCC v7Stage IV Cutaneous Melanoma AJCC v6 and v7

Interventions

BIOLOGICAL

DEC-205/NY-ESO-1 Fusion Protein CDX-1401

Given SC or ID

DRUG

Poly ICLC

Given SC

BIOLOGICAL

Recombinant Flt3 Ligand

Given SC

Trial Locations (7)

10016

Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York

10029

Mount Sinai Hospital, New York

27710

Duke University Medical Center, Durham

44195

Cleveland Clinic Foundation, Cleveland

53792

University of Wisconsin Hospital and Clinics, Madison

60637

University of Chicago Comprehensive Cancer Center, Chicago

97213

Providence Portland Medical Center, Portland

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH